Manu Chakravarthy
Chief Tech/Sci/R&D Officer at Carmot Therapeutics, Inc.
Manu Chakravarthy active positions
| Companies | Position | Start | End |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Chief Tech/Sci/R&D Officer | 2021-02-28 | - |
Career history of Manu Chakravarthy
Former positions of Manu Chakravarthy
| Companies | Position | Start | End |
|---|---|---|---|
| AXCA HEALPAR | Chief Tech/Sci/R&D Officer | 2017-07-31 | 2021-03-04 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 2015-07-31 | 2017-05-31 |
Training of Manu Chakravarthy
| Saint John's University | Undergraduate Degree |
| University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
| The University of Texas Medical School At Houston | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| AXCA HEALPAR | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Manu Chakravarthy
- Experience